Genmab HuMax-CD20 response rate increases post-study

By Angela McDaniels

Seattle, Dec. 1 - Genmab AS said one additional patient has responded to its HuMax-CD20, used for the treatment of relapsed or refractory follicular non-Hodgkin's lymphoma. This increases the objective response rate in patients who previously responded to rituximab treatment to 64%.

The phase 1/2 dose escalation trial divided 37 evaluable patients into four dose cohorts that received intravenous infusions of HuMax-CD20 once weekly for four weeks. Patients had previously received a median of 2 treatment regimens such as rituximab.

The objective response rates at each dose level were 63% for 300 mg, 33% for 500 mg, 20% for 700 mg and 60% for 1,000 mg, the company said.

These response rates include five complete responses, two complete responses unconfirmed - defined as a response that meets and exceeds the criteria for partial response - and nine partial responses. The data was originally reported in June.

The median duration of response and median time to disease progression in responding patients have not yet been reached after 12 months of follow up. Of the 16 patients who responded to treatment, 12 have not progressed at the end of the follow up period, the company said.

HuMax-CD20 was well tolerated, no dose limiting toxicities were reported and the maximum tolerated dose was not reached.

"We are particularly encouraged by the response rate in relapsed patients and look forward to the ongoing development of HuMax-CD20 in follicular lymphoma," said Lisa N. Drakeman, chief executive officer of Genmab, in a company news release.

Copenhagen-based Genmab AS is a biotechnology company that develops human antibodies for the treatment of life-threatening and debilitating diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.